leflunomide has been researched along with Sarcoidosis in 10 studies
Leflunomide: An isoxazole derivative that inhibits dihydroorotate dehydrogenase, the fourth enzyme in the pyrimidine biosynthetic pathway. It is used an immunosuppressive agent in the treatment of RHEUMATOID ARTHRITIS and PSORIATIC ARTHRITIS.
leflunomide : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 5-methyl-1,2-oxazole-4-carboxylic acid with the anilino group of 4-(trifluoromethyl)aniline. The prodrug of teriflunomide.
Sarcoidosis: An idiopathic systemic inflammatory granulomatous disorder comprised of epithelioid and multinucleated giant cells with little necrosis. It usually invades the lungs with fibrosis and may also involve lymph nodes, skin, liver, spleen, eyes, phalangeal bones, and parotid glands.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The records were reviewed from all patients treated at a tertiary sarcoidosis center from July 2002-July 2003, and information from patients treated with either leflunomide or methotrexate was analyzed for efficacy and toxicity." | 9.11 | Leflunomide for chronic sarcoidosis. ( Baughman, RP; Lower, EE, 2004) |
| "Leflunomide has been reported as an alternative therapy in sarcoidosis." | 7.77 | Effectiveness and safety of leflunomide for pulmonary and extrapulmonary sarcoidosis. ( Bandyopadhyay, D; Chapman, JT; Culver, DA; Lazar, CA; Parambil, JG; Pearson, K; Sahoo, DH; Xu, M, 2011) |
| "The records were reviewed from all patients treated at a tertiary sarcoidosis center from July 2002-July 2003, and information from patients treated with either leflunomide or methotrexate was analyzed for efficacy and toxicity." | 5.11 | Leflunomide for chronic sarcoidosis. ( Baughman, RP; Lower, EE, 2004) |
| "The widely accepted standard therapy for cutaneous sarcoidosis includes corticosteroids, antimalarials, and methotrexate." | 4.84 | Cutaneous sarcoidosis therapy updated. ( Badgwell, C; Rosen, T, 2007) |
| "Leflunomide has been reported as an alternative therapy in sarcoidosis." | 3.77 | Effectiveness and safety of leflunomide for pulmonary and extrapulmonary sarcoidosis. ( Bandyopadhyay, D; Chapman, JT; Culver, DA; Lazar, CA; Parambil, JG; Pearson, K; Sahoo, DH; Xu, M, 2011) |
| " A diagnosis of stage 2 sarcoidosis with pleural involvement was made and treatment with prednisone was started." | 3.75 | A 50-year-old man with stage 2 sarcoidosis with pleural involvement. ( Arrossi, A; Modrykamien, A; Reddy, A, 2009) |
| "Effective treatment of sarcoidosis potentially requires simultaneous modulation both M1/M2 polarization instead of suppressing one pathway over the other to restore immune competent and inactive (M0) macrophages." | 2.58 | Potential immunotherapies for sarcoidosis. ( Crouser, ED; Le, V, 2018) |
| "Sarcoidosis is a systemic, granulomatous disease that can affect multiple organs and has a variable clinical course." | 2.49 | Current therapy in sarcoidosis, the role of existing drugs and future medicine. ( Deneer, VH; Grutters, JC; van Moorsel, CH; Vorselaars, AD, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (40.00) | 29.6817 |
| 2010's | 6 (60.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Le, V | 1 |
| Crouser, ED | 1 |
| Vorselaars, AD | 1 |
| van Moorsel, CH | 1 |
| Deneer, VH | 1 |
| Grutters, JC | 1 |
| Bohelay, G | 1 |
| Bouaziz, JD | 1 |
| Nunes, H | 1 |
| Rybojad, M | 1 |
| Bagot, M | 1 |
| Petit, A | 1 |
| Laroche, L | 1 |
| Au, S | 1 |
| Mirsaeidi, M | 1 |
| Aronson, IK | 1 |
| Sweiss, NJ | 1 |
| Baughman, RP | 2 |
| Lower, EE | 2 |
| Modrykamien, A | 1 |
| Arrossi, A | 1 |
| Reddy, A | 1 |
| Sahoo, DH | 1 |
| Bandyopadhyay, D | 1 |
| Xu, M | 1 |
| Pearson, K | 1 |
| Parambil, JG | 1 |
| Lazar, CA | 1 |
| Chapman, JT | 1 |
| Culver, DA | 1 |
| Majithia, V | 1 |
| Sanders, S | 1 |
| Harisdangkul, V | 1 |
| Wilson, JG | 1 |
| Badgwell, C | 1 |
| Rosen, T | 1 |
4 reviews available for leflunomide and Sarcoidosis
| Article | Year |
|---|---|
Potential immunotherapies for sarcoidosis.
Topics: Anti-Bacterial Agents; Antibodies, Monoclonal, Humanized; Granuloma; Humans; Immunotherapy; Leflunom | 2018 |
Current therapy in sarcoidosis, the role of existing drugs and future medicine.
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Azathiopri | 2013 |
Treatment of Sarcoidosis.
Topics: Anti-Inflammatory Agents; Azathioprine; Clinical Trials as Topic; Drug Administration Schedule; Gran | 2015 |
Cutaneous sarcoidosis therapy updated.
Topics: Abnormalities, Drug-Induced; Adrenal Cortex Hormones; Allopurinol; Animals; Anti-Inflammatory Agents | 2007 |
1 trial available for leflunomide and Sarcoidosis
| Article | Year |
|---|---|
Leflunomide for chronic sarcoidosis.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Chronic Disease; Drug Therapy, Combination; Fe | 2004 |
5 other studies available for leflunomide and Sarcoidosis
| Article | Year |
|---|---|
Striking leflunomide efficacy against refractory cutaneous sarcoidosis.
Topics: Adjuvants, Immunologic; Anti-Inflammatory Agents, Non-Steroidal; Drug Therapy, Combination; Female; | 2014 |
Adalimumab Induced Subcutaneous Nodular Sarcoidosis; A Rare Side Effect of Tumor Necrosis Factor-α Inhibitor.
Topics: Adalimumab; Biopsy; Female; Humans; Immunosuppressive Agents; Isoxazoles; Leflunomide; Middle Aged; | 2014 |
A 50-year-old man with stage 2 sarcoidosis with pleural involvement.
Topics: Antirheumatic Agents; Dyspnea; Humans; Isoxazoles; Leflunomide; Lung; Male; Middle Aged; Pleural Dis | 2009 |
Effectiveness and safety of leflunomide for pulmonary and extrapulmonary sarcoidosis.
Topics: Adjuvants, Immunologic; Female; Humans; Isoxazoles; Leflunomide; Male; Middle Aged; Sarcoidosis; Sar | 2011 |
Successful treatment of sarcoidosis with leflunomide.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Humans; Immunosuppressive Agents; Isoxazoles; Leflun | 2003 |